FAGOFARMA
innovation in biotechnology
Clinical Trial
of TRIOFAG®
TRIOFAG® offers an innovative biological solution for the targeted treatment of bacterial respiratory infections. Developed by FAGOFARMA, this product contains carefully selected bacteriophages that attack and eliminate three key pathogens: Acinetobacter baumannii, Klebsiella pneumoniae, and Staphylococcus aureus.
Unlike conventional antibiotics, bacteriophages act with exceptional selectivity — they do not affect human cells or the natural microbiota, providing a gentler and more effective therapeutic approach. TRIOFAG® represents a new generation of therapy at a time when antibacterial resistance is one of the most pressing global health challenges.
The TRIOFAG® project is conducted in full compliance with Good Manufacturing Practice (GMP) and Good Clinical Practice (GCP) standards. Entering clinical trials marks a significant step forward in FAGOFARMA’s commitment to bringing bacteriophage therapy from research into clinical practice — precisely where it is needed most.
PROJECT TIMELINE
-
December 2022: Design of the TRIOFAG® phage cocktail
-
February 2024: Scientific advice received from the State Institute for Drug Control
-
February 2025: Repeated-dose oral toxicity study (GLP) demonstrates that TRIOFAG® is well tolerated and shows no adverse effects in Wistar rats
-
July 2025: First draft of the clinical trial protocol synopsis completed
-
March 2026: Planned application for clinical trial
FOR INVESTORS
Become part of the innovation in respiratory infection treatment.
FAGOFARMA offers an opportunity to invest in the clinical development of TRIOFAG®, a new generation of targeted bacteriophage therapy.
For more information, please do not hesitate to contact us.
